Evidence map›Paper›PMID 40810514›Full record

ArticlemBio2025

Targeting sphingolipid metabolism: inhibition of neutral sphingomyelinase 2 impairs coronaviral replication organelle formation.

Florian Salisch, Fabian Schumacher, Ulrich Gärtner, Burkhard Kleuser, John Ziebuhr, Christin Müller-Ruttloff

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Measles virus reprograms CD4Frontiers in cell and developmental biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Florian SalischInstitute of Medical Virology, Justus Liebig University Giessen, Giessen, Germany.
Fabian SchumacherInstitute of Pharmacy, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0001-8703-3275
Ulrich GärtnerInstitute of Anatomy and Cell Biology, Justus Liebig University Giessen, Giessen, Germany.
Burkhard KleuserInstitute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
John ZiebuhrInstitute of Medical Virology, Justus Liebig University Giessen, Giessen, Germany.ORCID 0000-0002-5741-8825
Christin Müller-RuttloffInstitute of Medical Virology, Justus Liebig University Giessen, Giessen, Germany.ORCID 0000-0002-6444-9478

Funding

Deutsche Forschungsgemeinschaft 530813989Deutsche Forschungsgemeinschaft GRK2581 project P09Deutsche Forschungsgemeinschaft GRK2581 project P10Deutsches Zentrum für Infektionsforschung TTU EIUniversity Medical Center Giessen and Marburg 06/2023Von-Behring-Röntgen-Stiftung 71_0016
6 · The paper itself

Abstract

Many plus-strand RNA viruses, including coronaviruses, orchestrate the formation of specialized replication organelles in the cytoplasm of infected cells by specific membrane-associated viral nonstructural proteins (nsp's). This process involves a massive reorganization of intracellular membrane compartments and is thought to depend on a specific set of cellular enzymes that synthesize or modify cellular lipids. Here, we investigated the potential role(s) of specific sphingolipids and related enzymes in coronavirus replication. We observed in cells infected with three different coronaviruses a comparable increase in global ceramide levels, whereas sphingomyelin levels were reduced, suggesting an enhanced conversion of sphingomyelin to ceramide by sphingomyelinases. To test this hypothesis, we targeted cellular sphingomyelinases using pharmacological and genetic approaches. The data obtained in these experiments led us to conclude that neutral sphingomyelinase 2 plays a critical role in an early (but not the entry) step of coronavirus replication in Huh-7-ACE2 cells. Furthermore, neutral sphingomyelinase 2 inhibited the formation of viral replication organelles, indicating the involvement of ceramide in the formation of these membrane structures. We also confirmed colocalization of neutral sphingomyelinase 2 and ceramide, but not sphingomyelin, with replication organelles that were produced in coronavirus-infected cells or induced by co-expression of coronavirus nsp3 and nsp4. A colocalization of ceramides with coronaviral replication organelles could be consistently demonstrated for different epithelial cell systems using genetically diverse coronaviruses, describing potential cell- and virus-type independence. IMPORTANCE: Coronaviruses are enveloped plus-strand RNA viruses with a broad host range, including humans. Human coronaviruses are not only associated with endemic, mild upper respiratory tract infections but also have pandemic potential and can be associated with a severe disease burden. The recent SARS-CoV-2 pandemic especially highlighted the urgent need to identify ideal broad-spectrum and host-targeted antiviral strategies. Since lipids are involved in every step of viral replication, we compared changes in the sphingolipid metabolism of cells infected with three different coronaviruses to identify similarities and related cellular enzymes involved in facilitating viral replication. We observed increased ceramide levels while sphingomyelin levels decreased, suggesting enhanced sphingomyelin-to-ceramide conversion by cellular sphingomyelinases upon infection. Impairment of neutral sphingomyelinase 2 reduced viral replication and the formation of virus-induced membranous replication organelles. Furthermore, we found that neutral sphingomyelinase 2 and its product ceramide were associated with viral replication organelles. Ceramides consistently appeared to be integral lipid building blocks of replication organelles across different human pathogenic coronaviruses and cell types. In conclusion, our study provides new insights into novel potentially conserved druggable sphingolipid-related host factors involved in coronaviral replication, offering potential new targets for antiviral therapies against newly emerging coronaviruses.

Indexed as

CoronavirusSphingolipidsSphingomyelin PhosphodiesteraseVirus ReplicationCell LineCeramidesHumansSARS-CoV-2SphingomyelinsCeramidesSphingolipidsSphingomyelin PhosphodiesteraseSphingomyelinscoronavirusHCoV-229Elipid metabolismreplication organellessphingomyelinaseviral replication

Identifiers

PMID40810514
PMCPMC12421859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.